ATE192338T1 - Pharmazeutisches präparat zur synergistischen aktivierung natürlicher killerzellen - Google Patents

Pharmazeutisches präparat zur synergistischen aktivierung natürlicher killerzellen

Info

Publication number
ATE192338T1
ATE192338T1 AT93913731T AT93913731T ATE192338T1 AT E192338 T1 ATE192338 T1 AT E192338T1 AT 93913731 T AT93913731 T AT 93913731T AT 93913731 T AT93913731 T AT 93913731T AT E192338 T1 ATE192338 T1 AT E192338T1
Authority
AT
Austria
Prior art keywords
pct
natural killer
killer cells
pharmaceutical preparation
date
Prior art date
Application number
AT93913731T
Other languages
English (en)
Inventor
Kristoffer Hellstrand
Svante Hermodsson
Original Assignee
Maxim Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Maxim Pharm Inc filed Critical Maxim Pharm Inc
Application granted granted Critical
Publication of ATE192338T1 publication Critical patent/ATE192338T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT93913731T 1992-06-03 1993-06-03 Pharmazeutisches präparat zur synergistischen aktivierung natürlicher killerzellen ATE192338T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9201719A SE513429C2 (sv) 1992-06-03 1992-06-03 Preparat för aktivering av naturliga mördarceller, vilket preparat innehåller interferon alfa och biogena aminer
PCT/SE1993/000496 WO1993024144A1 (en) 1992-06-03 1993-06-03 PREPARATION FOR ACTIVATION OF NATURAL KILLER CELLS (NK-CELLS), SAID PREPARATION CONTAINING INTERFERON-α AND HISTAMINE, SEROTONIN OR SUBSTANCES WITH CORRESPONDING RECEPTOR ACTIVITY

Publications (1)

Publication Number Publication Date
ATE192338T1 true ATE192338T1 (de) 2000-05-15

Family

ID=20386405

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93913731T ATE192338T1 (de) 1992-06-03 1993-06-03 Pharmazeutisches präparat zur synergistischen aktivierung natürlicher killerzellen

Country Status (12)

Country Link
US (1) US5728378A (de)
EP (1) EP0652768B1 (de)
JP (1) JP2888259B2 (de)
AT (1) ATE192338T1 (de)
CA (1) CA2136952C (de)
DE (1) DE69328558T2 (de)
DK (1) DK0652768T3 (de)
ES (1) ES2147758T3 (de)
GR (1) GR3033894T3 (de)
PT (1) PT652768E (de)
SE (1) SE513429C2 (de)
WO (1) WO1993024144A1 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6063373A (en) 1989-09-19 2000-05-16 Maxim Pharmaceuticals, Inc. Enhanced activation of NK cells using an NK cell activator and a hydrogen peroxide scavenger or inhibitor
US6003516A (en) * 1992-06-03 1999-12-21 Maxim Pharmaceuticals, Inc. Method for treatment of cancer and infectious disease
WO1994022448A1 (en) * 1993-03-26 1994-10-13 Beth Israel Hospital Association Topical and systemic application of buspirone or derivatives thereof for treatment of pathological conditions associated with immune responses
CA2196756A1 (en) * 1994-08-08 1996-02-22 Jan Urban Kristoffer Hellstrand Enhanced activation of natural killer cells using an nk cell activator and a hydrogen peroxide scavenger or inhibitor
AU778012B2 (en) * 1996-05-14 2004-11-11 Maxim Pharmaceuticals, Inc. Administration of histamine for therapeutic purposes
US5961969A (en) * 1996-05-14 1999-10-05 Maxim Pharmaceuticals, Inc. Stable circulating histamine levels
US6071942A (en) * 1996-05-14 2000-06-06 Maxim Pharmaceuticals, Inc. Elevation of circulating blood histamine levels
US6849452B1 (en) * 1998-03-03 2005-02-01 Institut Gustave Roussy Methods for activating natural killer (NK) cells and means for carrying out said methods
JP2002523378A (ja) * 1998-08-24 2002-07-30 マキシム ファーマシューティカルズ インコーポレイテッド Ｈ２−レセプターアゴニストおよび他のｔ−細胞活性化薬剤を用いたｔ−細胞（ｃｄ４＋およびｃｄ８＋）の活性化および保護
EP0998923A1 (de) * 1998-10-30 2000-05-10 Basf Aktiengesellschaft Verwendung von 5-HT7 Rezeptoragonisten zur Behandlung oder Vorbeugung von Ischämien
ES2310056T3 (es) 1998-12-23 2008-12-16 Maxim Pharmaceuticals, Inc. Sintesis de dihidrocloruro de histamina.
US6498181B1 (en) * 1999-01-06 2002-12-24 Maxim Pharmaceuticals Synergistic tumorcidal response induced by histamine
US6242473B1 (en) 1999-01-08 2001-06-05 Maxim Pharmaceuticals, Inc. Treatment and prevention of reactive oxygen metabolite-mediated cellular damage
US6153113A (en) 1999-02-22 2000-11-28 Cobe Laboratories, Inc. Method for using ligands in particle separation
US6354986B1 (en) 2000-02-16 2002-03-12 Gambro, Inc. Reverse-flow chamber purging during centrifugal separation
DE10043321B4 (de) * 2000-08-24 2005-07-28 Neurobiotec Gmbh Verwendung eines transdermalen therapeutischen Systems zur Behandlung der Parkinsonschen Krankheit, zur Behandlung und Prävention des prämenstruellen Syndroms und zur Lactationshemmung
DE10053397A1 (de) * 2000-10-20 2002-05-02 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
DE10064453A1 (de) * 2000-12-16 2002-07-04 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
KR20040058192A (ko) * 2001-10-19 2004-07-03 맥심 파마수티컬즈 인크. 간 질환 치료용으로서의 히스타민 용도
JP4808612B2 (ja) * 2003-04-25 2011-11-02 田辺三菱製薬株式会社 アルキレンジオキシベンゼン誘導体を含む経口投与用組成物
US20050171192A1 (en) * 2003-12-11 2005-08-04 Gehlsen Kurt R. Use of histamine to treat bone disease
US20060002913A1 (en) * 2004-06-22 2006-01-05 Gehlsen Kurt R Use of histamine and related compounds to treat disorders affecting muscle function
EP1712634A1 (de) * 2005-04-13 2006-10-18 Wittycell SAS Verfahren zur Auswahl von effizienten antigen präsentierenden Zellen und ihre Anwendung in der Regulation der Immunität
SG166716A1 (en) 2009-05-14 2010-12-29 Hsiehs Biotech Singapore Pte Ltd Lycopene and resveratrol compositions for nk cell activation resulting in anti-neoplastic effect
US20160000777A1 (en) * 2013-02-21 2016-01-07 University Of Rochester Methods of using histamine receptor agonists and antagonists
CN115925920B (zh) * 2022-08-04 2023-07-25 瑞因细胞工程科技(广州)有限公司 一种基因增强型免疫细胞治疗肝硬化的方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4863727A (en) * 1986-04-09 1989-09-05 Cetus Corporation Combination therapy using interleukin-2 and tumor necrosis factor
EP0295317A1 (de) * 1987-06-16 1988-12-21 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Pharmazeutische Zusammensetzung zur Behandlung von Tumoren
US5215744A (en) * 1987-06-16 1993-06-01 Boehringer Ingelheim Gmbh Methods for the treatment of tumors
US4883661A (en) * 1987-10-09 1989-11-28 Daly John M Use of arginine as an lymphokine synergist
US5026544A (en) * 1988-02-16 1991-06-25 Board Of Reagents, The University Of Texas System Methods and compositions for inhibiting the growth of neoplastic cells

Also Published As

Publication number Publication date
WO1993024144A1 (en) 1993-12-09
SE9201719L (sv) 1993-12-04
AU4366093A (en) 1993-12-30
SE513429C2 (sv) 2000-09-11
PT652768E (pt) 2000-09-29
ES2147758T3 (es) 2000-10-01
EP0652768B1 (de) 2000-05-03
US5728378A (en) 1998-03-17
CA2136952A1 (en) 1993-12-09
EP0652768A1 (de) 1995-05-17
AU672610B2 (en) 1996-10-10
DE69328558D1 (de) 2000-06-08
SE9201719D0 (sv) 1992-06-03
GR3033894T3 (en) 2000-11-30
DE69328558T2 (de) 2001-01-04
CA2136952C (en) 2005-08-09
JP2888259B2 (ja) 1999-05-10
JPH08502024A (ja) 1996-03-05
DK0652768T3 (da) 2000-08-07

Similar Documents

Publication Publication Date Title
DE69328558D1 (de) Pharmazeutisches Präparat zur synergistischen Aktivierung natürlicher Killerzellen
RU2214418C2 (ru) Аналоги glp-1
ATE324907T1 (de) Verbindung und arzneizusammensetzung zur verabreichung von wirkstoffen
ATE179429T1 (de) Cytokine dämpfende substanzen
EP0675708A1 (de) Pharmazeutische und dermokosmetische mittel enthaltend pferdecolostrum.
KR890700125A (ko) 신규 벤즈이미다졸 유도체, 그 제조방법 및 이 화합물을 함유하는 제약 조성물
IL87885A (en) Pharmaceutical compositions having antiprogestational and anti-estrogenic activities for the treatment of hormone- dependent tumors
DE69333023D1 (de) 3-beta-hydroxylierte natürliche Steroidderivate enthaltende Arzneimittelzusammensetzungen und ihre Verwendung
BR9916587A (pt) Aparelho e processo para preparar partìculas cristalinas de uma substância, população de partìculas, composição farmacêutica e partìculas cristalinas de 2,6-diamino-3-(2,3,5-triclorofenil)-pirazina
YU47543B (sh) Postupak za dobijanje farmaceutskog preparata za stimulaciju granulocita
DE69722191D1 (de) Dosiszusammensetzung mit modifizierter freigabe aus vielen einzelkomponenten
NO954320L (no) Lyosfærer omfattende gonadotropin
ES2157993T3 (es) Benzoilguanidinas, su preparacion y su uso en medicamentos.
DE69506007D1 (de) Transdermales system zur gleichzeitigen verabreichung von mehreren wirkstoffen
DE59406938D1 (de) Pharmazeutische zubereitungen mit einem wirkstoff, der modifizierte amidingruppen enthält
ATE205400T1 (de) Unterdrückung proliferativer reaktionen und induktion von toleranz durch polymorphe typ ii- spezifische mhc allopeptide
DK0633763T3 (da) Kosmetiske eller farmaceutiske sammensætninger indeholdende deacylerede glycerophospholipider til topisk brug
EP0173664A3 (de) Biologisch aktive Benzimidazolderivate und Verfahren zu ihrer Herstellung
NO933345D0 (no) Forbedrede retardsystemer for tidsforsinket frisetting avmedisinske og/eller biologiske aktive bestanddeler fra etdepot-baerermateriale
NO306700B1 (no) Farmasöytiske preparater for rektal administrering, inneholdende alkylsulfonamider som er HT1-agonister
AU666422B2 (en) Novel bicyclic pyrimidine compounds, method for preparing same and pharmaceutical compositions containing said compounds
Serrate et al. Association of human natural killer cell activity against human primary tumors with large granular lymphocytes
DK0722325T3 (da) Præparat til behandling eller forebyggelse af herpes
ATE169021T1 (de) Cephalostatin-analoga und ihre verwendung als antitumormittel
ES2087178T3 (es) Disulfato de ws7622a, procedimiento para su preparacion y su uso.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee